Company news

EyePoint, Inc. news in 2021

EyePoint, Inc.'s news releases, calls and decks from 2021, newest first.

View company

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

December 6, 2021

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

November 18, 2021

EyePoint Pharmaceuticals Announces Pricing of Public Offering

November 15, 2021

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

November 12, 2021

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

November 4, 2021

EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

November 2, 2021

EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer

October 31, 2021

EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

October 26, 2021

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

October 11, 2021

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

September 16, 2021

EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

August 9, 2021

EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

August 3, 2021

EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

August 1, 2021

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

July 27, 2021

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

July 19, 2021

EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

July 5, 2021

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

June 30, 2021

EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

June 27, 2021

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

May 25, 2021

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

May 24, 2021

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments

May 4, 2021

EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021

April 27, 2021

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments

March 3, 2021

EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

February 24, 2021

EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock

February 3, 2021

EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 31, 2021

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

January 27, 2021

EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues

January 10, 2021

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics

January 2, 2021

Calls in 2021

Decks in 2021